1 with moderate-to-severe rhinitis than FP and azelastine.

2 3]) more than FP (-5.1 [SD, 4.9], P < .001), azelastine (-4.4 [SD, 4.8], P < .001), or placebo (-3.0

3                The results demonstrated that azelastine, 6 mg twice per day, can reduce the need for

4 bitor of mast cell degranulation, but not by azelastine, a histamine receptor 1 antagonist, or by ket

5  efficacy of MP29-02 (a novel formulation of azelastine and fluticasone propionate [FP]) in patients

6  with 2 first-line therapies (ie, intranasal azelastine and intranasal FP) in this population.

7 ess commonly used in clinical practice (i.e. azelastine, chlorpheniramine, hydroxyzine, and ketotifen

8                                              Azelastine-fluticasone displayed the highest probability

9                Among individual medications, azelastine-fluticasone, and fluticasone furoate were the

10                              In seasonal AR, azelastine-fluticasone, fluticasone furoate, and flutica

11                                          The azelastine group also had a statistically significantly

12                   Compared with placebo, the azelastine group had a statistically significantly great

13                           MP-AzeFlu combines azelastine hydrochloride, FP and a novel formulation in

14 valuate the corticosteroid-sparing effect of azelastine in patients with chronic bronchial asthma.

15  loratadine), intranasal antihistamines (eg, azelastine, olopatadine), and intranasal corticosteroids

16 atadine) or an intranasal antihistamine (eg, azelastine, olopatadine), whereas patients with persiste

17 atment with histamine receptor-1 antagonist, azelastine prevented the early effect of nasal secretion

18 ified three drugs (ibutilide, azaperone, and azelastine) that increase K(V)11.1 trafficking.

19 otal of 193 subjects received either 6 mg of azelastine twice per day or placebo (in a 2:1 ratio) in

20 n inhaled corticosteroids (4.9 puffs/day for azelastine versus 3.1 puffs/day for placebo; p < or = 0.

21 aseline level (53 and 31%, respectively, for azelastine versus 34 and 14%, respectively, for placebo;